Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 2/20 | 0.56 |
| ▸ | THRA | P10827 | 13/20 | 0.47 |
| ▸ | THRB | P10828 | 13/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | USP8 | P40818 | 1/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10419916 | 0.83 | GRM1 (0.45) | BCAT1THRATHRBCYP2C8CYP2C9 | |
| SCHEMBL16703956 | 0.81 | L3MBTL1 (0.60) | THRATHRBCYP2C8CYP2C9SMN1; SMN2 | |
| SCHEMBL13548230 | 0.81 | THRA (0.43) | BCAT1THRATHRBCYP2C8CYP2C9 | |
| SCHEMBL10925020 | 0.80 | BCAT1 (0.39) | BCAT1THRATHRBCYP2C8CYP2C9 | |
| SCHEMBL10925017 | 0.80 | BCAT1 (0.39) | BCAT1THRATHRBCYP2C8CYP2C9 | |
| SCHEMBL29789606 | 0.79 | THRA (0.55) | BCAT1THRATHRBCYP2C8CYP2C9 | |
| SCHEMBL3584424 | 0.79 | HPN (0.47) | THRATHRBCYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL23168767 | 0.78 | THRA (0.58) | BCAT1THRATHRBCYP2C8CYP2C9 | |
| SCHEMBL16709414 | 0.78 | THRA (0.43) | BCAT1THRATHRBCYP2C8CYP2C9 | |
| SCHEMBL4070661 | 0.78 | THRA (0.46) | BCAT1THRATHRBCYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107652300-B | The podophyllotoxin analogue of the structure of triazinone containing 1,2,4- and its application | 辽宁大学 | 2019-08-09 | — | — | CN | claimed |
| EP-3927693-B1 | 2-PHENYL-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS THYROID HORMONE RECEPTOR AGONISTS FOR THE TREATMENT OF E.G. OBESITY | NANJING RUIJIE PHARMA CO LTD (CN) | 2026-05-06 | — | — | EP | disclosed |
| CN-112300133-B | Heterocyclic compound and application thereof | 深圳微芯生物科技股份有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-113620873-B | Preparation method and application of zinc-containing binding group and quinoline skeleton compound | 沈阳药科大学 | 2023-12-08 | — | — | CN | disclosed |
| WO-2022184177-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 甫康（上海）健康科技有限责任公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-114685450-A | 2-pyridone derivative, preparation method and medical application thereof | 昆药集团股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-113620873-A | Preparation method and application of compound containing zinc binding group and quinoline skeleton | 沈阳药科大学 | 2021-11-09 | — | — | CN | disclosed |
| CN-112876457-A | Novel 4-phenoxypyridine derivative and application thereof | 辽宁大学 | 2021-06-01 | — | — | CN | disclosed |
| WO-2021078274-A1 | PYRIDAZINONE OR PYRIDAZINE COMPOUND AND DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | 苏州泽璟生物制药股份有限公司 | 2021-04-29 | — | — | WO | disclosed |
| CN-110684013-A | 4-phenoxypyridine derivatives containing 3-pyridazinone, 4-pyridazinone and 1,2, 4-triazinone structures and application thereof | 辽宁大学 | 2020-01-14 | — | — | CN | disclosed |
| US-20140371221-A1 | QUINOLINE COMPOUND COMPOSING 1,2,4-TRIAZINE-DIONE AND USE THEREOF | WUHAN SHENGYUN BIOPHARMA CO., LTD. (CN) | 2014-12-18 | — | — | US | disclosed |
| US-8822465-B2 | Quinoline compound composing 1,2,4-triazine-dione and use thereof | WUHAN SHENGYUN BIOPHARMA CO., LTD. (CN) | 2014-09-02 | — | — | US | disclosed |
| US-20130252958-A1 | QUINOLINE COMPOUND COMPOSING 1,2,4-TRIAZINE-DIONE AND USE THEREOF | WUHAN SHENGYUN BIOPHARMA CO., LTD. (CN) | 2013-09-26 | — | — | US | disclosed |
| US-7015230-B1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | disclosed |
| US-6716838-B1 | INHIBITORS OF SERINE PROTEASES OF THE COAGULATION CASCADE | PHARMACIA CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20030023086-A1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6458952-B1 | ENZYME INHIBITORS FOR SERINE METHODS FOR PREVENTING AND TREATING THROMBOTIC CONDITIONS SUCH AS CORONARY ARTERY AND CEREBROVASCULAR DISEASE WITH COMPOUNDS THAT INHIBIT SERINE PROTEASES OF THE COAGULATION CASCADE. | PHARMACIA CORPORATION | 2002-10-01 | — | — | US | disclosed |
| EP-1178971-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS | Pharmacia Corporation (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001087852-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069833-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252958-A1 | QUINOLINE COMPOUND COMPOSING 1,2,4-TRIAZINE-DIONE AND USE THEREOF | MET, RET, KRAS | BCAT1 4305/4885THRA 523/4885THRB 576/4885 |
| US-20030023086-A1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | TFPI, PLAT, PLAU | BCAT1 371/4885THRA 3792/4885THRB 3270/4885 |
| US-20140371221-A1 | QUINOLINE COMPOUND COMPOSING 1,2,4-TRIAZINE-DIONE AND USE THEREOF | RET, MET, RAF1 | BCAT1 4229/4885THRA 349/4885THRB 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.